Overview
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)
Status:
Recruiting
Recruiting
Trial end date:
2022-06-30
2022-06-30
Target enrollment:
Participant gender: